LDX received FDA approval - "MELBOURNE, Australia (3 July 2023) – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a
leader in rapid, point-of-care (POC) diagnostic technologies, is pleased to announce that it has received
clearance from the US Food and Drug Administration (FDA) to market its FebriDx® rapid, point-of-care
test in the United States."
BOT - Anything but charting, page-6213
-
- There are more pages in this discussion • 3,212 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $678.7M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1339 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 11500 | 2 |
View Market Depth
| Last trade - 09.48am 26/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
Day chart unavailable